AngioDynamics, Inc.
Reported: 2026-01-06
AngioDynamics reported strong overall performance in Q2 FY2026, with revenue growth of 8.8% and nearly doubled adjusted EBITDA year-over-year, prompting an increase in full-year guidance.
Key takeaways
- MedTech revenue surged by 13%, driven primarily by continued strong performance from the Auryon platform, marking its 18th consecutive quarter of double-digit growth.
- Significant regulatory advancements were achieved in the mechanical thrombectomy portfolio, including IDE approvals for key studies that enhance competitive positioning and clinical applications.
- The NanoKnife system benefitted from increased procedure volumes following the recent CPT code activation, positioning the company well for future market growth.
